2661 — QingSong Health Income Statement
0.000.00%
Last trade - 00:00- HK$4.99bn
- HK$3.89bn
- CNY1.26bn
Annual income statement for QingSong Health, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 394 | 490 | 945 | 1,256 |
| Cost of Revenue | ||||
| Gross Profit | 325 | 391 | 362 | 435 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 387 | 385 | 938 | 1,635 |
| Operating Profit | 6.34 | 105 | 7.38 | -379 |
| Net Income Before Taxes | 6.34 | 105 | 7.38 | -379 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -9.1 | 97.2 | 8.99 | -380 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Extraordinary Items | ||||
| Net Income | -2.06 | 73.6 | 10.4 | -380 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -2.06 | 73.6 | 10.4 | -380 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.049 | 0.45 | 0.08 | -1.67 |